Recursion Announces Data Collaboration Deal With Tempus, Top 50 Supercomputer Ambition Powered By NVIDIA, And Updated Focus Of Collaboration With Bayer To Precision Oncology
Portfolio Pulse from Benzinga Newsdesk
Recursion (NASDAQ:RXRX) has announced a data collaboration deal with Tempus Labs, an ambition to build a top 50 supercomputer powered by NVIDIA (NASDAQ:NVDA), and an updated focus of collaboration with Bayer in precision oncology. Recursion will pay Tempus up to $160M over the next five years for access to one of the world's largest proprietary oncology datasets. The company also plans to quadruple its supercomputing power with NVIDIA's support. Additionally, Recursion and Bayer will initiate up to seven oncology programs, with Recursion eligible to receive up to $1.5 billion plus royalties on net sales.
November 09, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NVIDIA's collaboration with Recursion to quadruple its supercomputing power could strengthen its position in the biopharma industry and potentially lead to increased sales of its GPUs.
NVIDIA's collaboration with Recursion could increase demand for its GPUs in the biopharma industry, potentially leading to increased sales and revenues.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Recursion's collaborations with Tempus, NVIDIA, and Bayer could significantly enhance its capabilities in precision oncology and drug discovery, potentially leading to increased revenues in the future.
The collaborations with Tempus, NVIDIA, and Bayer could provide Recursion with valuable resources and expertise, potentially accelerating its drug discovery efforts and enhancing its position in the precision oncology market.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100